AtriCure (ATRC) Tops Q4 EPS by 2c ; Offers Guidance

AtriCure (NASDAQ: ATRC) reported Q4 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $106.5 million versus the consensus estimate of $103.37 million.

GUIDANCE:

AtriCure sees FY2024 EPS of ($0.74)-($0.82), versus the consensus of ($0.69). AtriCure sees FY2024 revenue of $459-466 million, versus the consensus of $458.4 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)
• LeonaBio, Inc. (LONA) Tops Q2 EPS by 32c